Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 911-913, 2005; 10.1373/clinchem.2004.046169
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kovacs, A.
Right arrow Articles by Tornvall, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kovacs, A.
Right arrow Articles by Tornvall, P.
Related Collections
Right arrow Clinical Immunology
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:911-913.)
© 2005 American Association for Clinical Chemistry, Inc.

Technical Briefs

Hormonal Regulation of Circulating C-Reactive Protein in Men

Alexander Kovacs1,2, Peter Henriksson3, Anders Hamsten1,2, Håkan Wallén3, Johan Björkegren2 and Per Tornvall1,2,a

1 Department of Cardiology and 2 Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska University Hospital, and 3 Department of Medicine, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden

aaddress correspondence to this author at: Department of Cardiology, Karolinska University Hospital, S-17176 Stockholm, Sweden; fax 46-8-311044, e-mail per.tornvall@karolinska.se

The first 20% of the full text of this article appears below.

The plasma concentration of C-reactive protein (CRP), measured by high-sensitivity methods, is a reliable marker of risk of future coronary heart disease (CHD) in healthy individuals (1)(2) and of CHD death in patients with unstable angina pectoris or non-Q-wave myocardial infarction (3). The possibility of hormonal regulation of circulating CRP is of great interest because male gender is considered an independent risk factor for CHD and estrogen has many beneficial cardiovascular effects in women (4).

Both in vivo and in vitro data support the hypothesis that interleukin-6 (IL-6) is the main inducer of the acute-phase CRP response, but other factors such as IL-1ß might potentiate IL-6 stimulation of CRP (5). The factors determining unstimulated CRP expression are less known.

Because of the strong association between CRP and CHD and the fact that previous studies have shown that CRP to a large extent is regulated on the transcriptional level (5), it is of great interest to identify factors that regulate CRP production. A study of randomized treatment of prostate cancer by orchidectomy or estrogen allowed us to investigate the hormonal influence on circulating CRP concentrations in middle-aged and elderly men.

A total of 100 consecutive patients with prostate cancer suitable for hormonal therapy were enrolled in the study. Patients were randomized to either orchidectomy or estrogen treatment. The estrogen regimen was 160 mg of polyestradiol phosphate intramuscularly every month during the first 3 months, then . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.